SEC Comment Letter 0000000000-23-007995 to Baudax Bio, Inc. (BXRXQ) (CIK 0001780097)
Baudax Bio, Inc. (BXRXQ) (CIK 0001780097)
Date: July 26, 2023 · CIK: 0001780097 · Accession: 0000000000-23-007995
AI Filing Summary & Sentiment
File numbers found in text: 333-272994
Letter
United States securities and exchange commission logo July 26, 2023 Gerri Henwood President and Chief Executive Officer Baudax Bio, Inc. 490 Lapp Road Malvern, PA 19355 Re:Baudax Bio, Inc. Registration Statement on Form S-3 Filed June 28, 2023 File No. 333-272994 Dear Gerri Henwood: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Jordan Nimitz at 202-551-5831 with any questions. Sincerely, Division of Corporation Finance Office of Industrial Applications and Services cc: Jennifer Porter, Esq.
Show Raw Text
United States securities and exchange commission logo
July 26, 2023
Gerri Henwood
President and Chief Executive Officer
Baudax Bio, Inc.
490 Lapp Road
Malvern, PA 19355
Re:Baudax Bio, Inc.
Registration Statement on Form S-3
Filed June 28, 2023
File No. 333-272994
Dear Gerri Henwood:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Jordan Nimitz at 202-551-5831 with any questions.
Sincerely,
Division of Corporation Finance
Office of Industrial Applications and
Services
cc: Jennifer Porter, Esq.